• Explore /
  • Poster
  • / Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

Abstract Poster

Authors

null

Richard S. Finn

David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA

Richard S. Finn , Stephen L. Chan , Andrew X. Zhu , Jennifer J. Knox , Ann-Lii Cheng , Abby B. Siegel , Oliver Bautista , Masatoshi Kudo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02702401

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4143)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4143

Abstract #

TPS4143

Poster Bd #

129a

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

Poster

2017 Gastrointestinal Cancers Symposium

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.

First Author: Andrew X. Zhu

First Author: Shukui Qin

First Author: Shukui Qin